Kindred Biosciences, Inc., a biopharmaceutical company, is developing biologics that focus on the lives of pets. The company has a pipeline of novel biologics in development across various therapeutic classes and intellectual property portfolio. Its programs under development include interleukin-31 and interleukin-4R for canine atopic dermatitis; KIND-030 for parvovirus in dogs; KIND-510a for the control of non-regenerative anemia in cats; anti-TNF antibody for inflammatory bowel disease in dogs; and other biologics candidates. The company was founded in 2012 and is headquartered in Burlingame, California.
Show more...
首席执行官
Richard Chin
员工
63
国家
US
上市
0 Comments
分享你的想法
FAQ
Kindred Biosciences 今天的股价是多少?▼
KIN 当前价格为 $9.25 USD,过去 24 小时上涨了 +0.11%。在图表上更密切关注 Kindred Biosciences 股价表现。
Kindred Biosciences 的股票代码是什么?▼
根据交易所不同,股票代码可能会有所不同。例如,在 交易所,Kindred Biosciences 的股票以代码 KIN 进行交易。